Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jun Tie

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Eclinicalmedicine|February 18, 2026
Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic agents in intermediate-stage hepatocellular carcinoma (CHANCE2202): a target trial emulation studyJian-Jian Chen, Zhi-Cheng Jin, Jia-Wei Zhou, et al.
Eclinicalmedicine|May 15, 2024
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation studyZhi-Cheng Jin, Jian-Jian Chen, Xiao-Li Zhu, et al.
Liver Cancer|June 23, 2025
Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition)Yu Yang, Juxian Sun, Jianqiang Cai, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Eclinicalmedicine|February 18, 2026
Transarterial chemoembolization (TACE) combined with immunotherapy and anti-angiogenic agents in intermediate-stage hepatocellular carcinoma (CHANCE2202): a target trial emulation studyJian-Jian Chen, Zhi-Cheng Jin, Jia-Wei Zhou, et al.
Eclinicalmedicine|May 15, 2024
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation studyZhi-Cheng Jin, Jian-Jian Chen, Xiao-Li Zhu, et al.
Liver Cancer|June 23, 2025
Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition)Yu Yang, Juxian Sun, Jianqiang Cai, et al.
Pageof 8